Google Search Trends to Assess Public Interest and Concern About Pegcetacoplan for the Treatment of Geographic Atrophy
View abstract on PubMed
Summary
This summary is machine-generated.Public interest in Syfovre (pegcetacoplan), a new geographic atrophy treatment, surged around its FDA approval and market launch. Retinal vasculitis and East Coast searches were notable trends.
Area Of Science
- Ophthalmology
- Pharmacovigilance
- Digital Health Trends
Background
- Geographic atrophy (GA) is a leading cause of irreversible vision loss.
- The recent FDA approval of Syfovre (pegcetacoplan) marks a significant advancement in GA treatment options.
- Understanding public interest is crucial for assessing treatment adoption and impact.
Purpose Of The Study
- To evaluate global public interest and search trends for Syfovre (pegcetacoplan).
- To correlate search interest with key events like FDA approval and market introduction.
- To identify specific areas of public concern, such as side effects and geographic variations.
Main Methods
- Utilized Google Trends to analyze search volumes for "Syfovre" from October 2022 to October 2023.
- Identified peaks in relative search volume (RSV) and correlated them with drug approval and market launch dates.
- Examined search interest related to specific side effects, notably "retinal vasculitis".
Main Results
- Significant spikes in "Syfovre" search volume occurred in February, March, and April 2023, aligning with FDA approval and market release.
- Retinal vasculitis emerged as a prominent search topic, with a notable RSV increase in July 2023.
- Higher search interest for Syfovre was concentrated among users on the U.S. East Coast.
Conclusions
- Google Trends effectively monitors public engagement with new treatments like Syfovre for geographic atrophy.
- Search data provides valuable insights into public perception and concerns regarding novel therapies.
- This methodology can inform public health communication and patient education strategies.

